Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis
卡瑞利珠单抗（一种抗PD-1抗体）联合VEGFR-2抑制剂阿帕替尼和化疗作为三阴性乳腺癌新辅助治疗的探索性II期临床试验（NeoPanDa03）：疗效、安全性和生物标志物分析
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02337-1
Liu, Xiaoxiao; Zhuang, Chunying; Liu, Lei; Xiong, Ling; Xie, Xin; He, Ping; Li, Juanjuan; Wei, Bing; Yan, Xi; Tian, Tinglun; Zhong, Xiaorong; Chen, Jie; Cheng, Yan; Zheng, Dan; Cheng, Peng; Sun, Tianlin; Li, Weiwei; Zhu, Changbin; Chen, Shuaitong; Fang, Chao; Fu, Jun; Li, Shibao; Jing, Jing; Luo, Ting
